Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire …
Termination Results From Rio Grande’s Request to Renegotiate Terms of Acquisition LOS ANGELES, CA–(Marketwired – Aug 19, 2016) – Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a developer of bioelectronic devices and non-invasive Electroceuticals for the treatment of inflammatory conditions in vital organs, announced today that the binding letter agreement (LOI) to acquire Rio Grande Neurosciences (RGN), announced on July 11, 2016, has been dissolved effective today. The Company will not be proceeding with the acquisition. The binding LOI was terminated by RGN’s CEO following its request to renegotiate the terms of the binding-LOI, including the aggregate purchase price and the removal of non-solicitation of the binding letter agreement. Our board of directors has determined we are better served by this decision. As a result, the $500,000 note…
Link to Full Article: Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire …
Sharing
